Randomized phase-II trial of abiraterone acetate plus LHRH-therapy versus abiraterone acetate sparing LHRH-therapy in patients with progressive chemotherapy-naive castration-resistant prostate cancer (SPARE)

Trial Profile

Randomized phase-II trial of abiraterone acetate plus LHRH-therapy versus abiraterone acetate sparing LHRH-therapy in patients with progressive chemotherapy-naive castration-resistant prostate cancer (SPARE)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2014

At a glance

  • Drugs Abiraterone acetate (Primary) ; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms SPARE
  • Most Recent Events

    • 12 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top